# **Recognizing Medical Necessity for iDose TR**



# Document the rationale for the treatment choice



Non-compliant/non-adherent to topical glaucoma medications (with clinical rationale)



Uncontrolled on topical glaucoma medication(s)



Intolerant or allergic to topical medication(s)



Underlying co-morbidities (e.g. ocular surface disease)



Experienced side effects on topical medications that have affected quality of life



Underwent prior intervention and remain in need of therapy

Have questions, or need extra assistance? Contact your local Reimbursement Liaison.

For patients with Commercial insurance or Medicare Advantage plans, a prior authorization is necessary to ensure coverage for iDose TR.

## **Indications And Usage**

iDose TR (travoprost intracameral implant) is indicated for the reduction of intraocular pressure (IOP) in patients with open angle glaucoma (OAG) orocular hypertension (OHT).

## **Important Safety Information**

#### **Dosage and Administration**

For ophthalmic intracameral administration. The intracameral administration should be carried out under standard aseptic conditions.

#### Contraindications

iDose TR is contraindicated in patients with active or suspected ocular or periocular infections, patients with corneal endothelial cell dystrophy (e.g., Fuch's Dystrophy, corneal guttatae), patients with prior corneal transplantation, or endothelial cell transplants (e.g., Descemet's Stripping Automated Endothelial Keratoplasty [DSAEK]), patients with hypersensitivity to travoprost or to any other components of the product.

## **Warnings and Precautions**

iDose TR should be used with caution in patients with narrow angles or other angle abnormalities. Monitor patients routinely to confirm the location of the iDose TR at the site of administration. Increased pigmentation of the iris can occur. Iris pigmentation is likely to be permanent.

#### **Adverse Reactions**

In controlled studies, the most common ocular adverse reactions reported in 2% to 6% of patients were increases in intraocular pressure, iritis, dry eye, visual field defects, eye pain, ocular hyperaemia, and reduced visual acuity.

## Please See Full Prescribing Information.

You are encouraged to report all side effects to the FDA.

Visit www.fda.gov/medwatch, or call 1-800-FDA-1088. You may also call Glaukos at 1-888-404-1644.

